Can-Fite BioPharma (ADR) (CANF)
Develops oral A3AR-targeted drug candidates for psoriasis, liver cancer and metabolic liver disease.
$2.40
Pre-market+0.03 (+1.32%)
At close$2.37(−27.96%)
Something off on this page? Send us feedback.
EPSReportedEstimate
Aug '24Jan '25Mar '25Apr '25Aug '25Mar '26Aug '26Aug '26
Reported$0.00−$0.27$0.00−$0.10$0.00−$5.97−$0.33−$0.33
Estimate−$0.36−$0.27−$0.24−$0.10−$4.15−$27.00−$0.33−$0.33
Surprise+99.4%0.0%+99.3%0.0%+100.0%+77.9%0.0%0.0%
RevenueReportedEstimate
Aug '24Jan '25Mar '25Apr '25Aug '25Mar '26Aug '26Aug '26
Reported$100.0K$300.0K$179.0K$101.0K$202.0K$203.0K——
Estimate$300.0K$150.0K$150.0K$500.0K$500.0K$300.0K$300.0K$300.0K
Surprise−66.7%+100.0%+19.3%−79.8%−59.6%−32.3%——
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Aug 2026 | −$0.33 | −$0.33 | 0.0% |
| Aug 2026 | −$0.33 | −$0.33 | 0.0% |
| Apr 2026 | −$27.00 | — | — |
| Mar 2026 | −$27.00 | −$5.97 | +77.9% |
| Aug 2025 | −$4.15 | $0.00 | +100.0% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Apr 2025 | |||
| Mar 2025 | |||
| Jan 2025 | |||
| Aug 2024 | |||
| Jul 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| Jun 2019 | |||
| Apr 2019 | |||
| Jan 2019 | |||
| Aug 2018 | |||
| Jun 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Sep 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Apr 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| May 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | −$0.33 | −$0.33 | 0.0% | $300.0K | — | — | +3.5% |
| Aug 27, 2026 | −$0.33 | −$0.33 | 0.0% | $300.0K | — | — | +0.9% |
| Apr 13, 2026 | −$27.00 | — | — | $300.0K | — | — | — |
| Mar 26, 2026 | −$27.00 | −$5.97 | +77.9% | $300.0K | $203.0K | −32.3% | −4.6% |
| Aug 28, 2025 | −$4.15 | $0.00 | +100.0% | $500.0K | $202.0K | −59.6% | −4.6% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Apr 14, 2025 | |||||||
| Mar 27, 2025 | |||||||
| Jan 2, 2025 | |||||||
| Aug 29, 2024 | |||||||
| Jul 4, 2024 | |||||||
| Mar 28, 2024 | |||||||
| Nov 30, 2023 | |||||||
| Aug 31, 2023 | |||||||
| Jun 1, 2023 | |||||||
| Mar 30, 2023 | |||||||
| Nov 25, 2022 | |||||||
| Aug 25, 2022 | |||||||
| May 26, 2022 | |||||||
| Mar 24, 2022 | |||||||
| Nov 26, 2021 | |||||||
| Aug 26, 2021 | |||||||
| May 27, 2021 | |||||||
| Mar 25, 2021 | |||||||
| Nov 30, 2020 | |||||||
| Aug 27, 2020 | |||||||
| Jun 10, 2020 | |||||||
| Mar 27, 2020 | |||||||
| Nov 29, 2019 | |||||||
| Aug 30, 2019 | |||||||
| Jun 10, 2019 | |||||||
| Apr 12, 2019 | |||||||
| Jan 17, 2019 | |||||||
| Aug 31, 2018 | |||||||
| Jun 1, 2018 | |||||||
| Mar 23, 2018 | |||||||
| Nov 27, 2017 | |||||||
| Sep 1, 2017 | |||||||
| May 30, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Nov 25, 2016 | |||||||
| Aug 26, 2016 | |||||||
| May 27, 2016 | |||||||
| Apr 1, 2016 | |||||||
| Nov 27, 2015 | |||||||
| Aug 27, 2015 | |||||||
| May 29, 2015 | |||||||